Clinical Trial

Study of ALK-001 on the Progression of Stargardt Disease

Name: Study of ALK-001 on the Progression of Stargardt Disease — clinical trial record (NCT07419334)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NORTHSTAR

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-10

Trial Details

NCT Number	NCT07419334
Lead Sponsor	Alkeus Pharmaceuticals, Inc.
Conditions	Stargardt Disease
Enrollment	230 participants
Start Date	2026-06
Primary Completion	2029-10 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-28